2/27/2009

The FDA postponed its clearance of telavancin, Theravance's drug candidate for superbugs in skin infections, and sought more information on the safety of usage in patients with kidney risk factors. The agency's complete-response letter also recommends the addition of a "black box" warning for pregnant women. Theravance CEO Rick Winningham said the company intends to respond "promptly" to the FDA's concerns.

Related Summaries